ORG 28611Alternative Names: SCH 900111
Latest Information Update: 20 Oct 2009
At a glance
- Originator Organon
- Class Anaesthetics
- Mechanism of Action Cannabinoid receptor CB1 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anaesthesia
Most Recent Events
- 20 Oct 2009 Discontinued - Phase-I for Anaesthesia in USA (unspecified route)
- 19 Nov 2007 Organon has been acquired by Schering-Plough